The DOI matches its Crossref record.
In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria
Open accessAbstract
The in vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) were assessed in an experimental murine thigh infection model in neutropenic mice. Mice were infected with one of several strains of Streptococcus pneumoniae , Staphylococcus aureus , Escherichia coli , or Klebsiella pneumoniae . Most infections were treated with a twice-daily dosing schedule, with administration of 0.75 to 192 mg of GAR-936 or WAY 152,288 per kg of body weight. A maximum-effect dose-response model was used to calculate the dose that produced a net bacteriostatic effect over 24 h of therapy. This dose was called the bacteriostatic dose. More extensive dosing studies were performed with S. pneumoniae 1199, E. coli ATCC 25922, and K. pneumoniae ATCC 43816, with doses being given as one, two, four, or eight equal doses over a period of 24 h. The dosing schedules were designed in order to minimize the interrelationship between the various pharmacokinetic and pharmacodynamic parameters studied. These parameters were time above 0.03 to 32 times the MIC, area under the concentration-time curve (AUC), and maximum concentration of drug in serum ( C max ). The bacteriostatic dose remained essentially the same, irrespective of the dosing frequency, for S. pneumoniae 1199 (0.3 to 0.9 mg/kg/day). For E. coli ATCC 25922 and K. pneumoniae ATCC 43816, however, more frequent dosing led to lower bacteriostatic doses. Pharmacokinetic studies demonstrated dose-dependent elimination half-lives of 1.05 to 2.34 and 1.65 to 3.36 h and serum protein bindings of 59 and 71% for GAR-936 and WAY 152,288, respectively. GAR-936 and WAY 152,288 were similarly effective against the microorganisms studied, with small differences in maximum effect and 50% effective dose. The glycylcyclines were also similarly effective against tetracycline-sensitive and tetracycline-resistant bacteria. Time above a certain factor (range, 0.5 to 4 times) of the MIC was a better predictor of in vivo efficacy than C max or AUC for most organism-drug combinations. The results demonstrate that in order to achieve 80% maximum efficacy, the concentration of unbound drug in serum should be maintained above the MIC for at least 50% of the time for GAR-936 and for at least 75% of the time for WAY 152,288. The results of these experiments will aid in the rational design of dose-finding studies for these glycylcyclines in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines
Agwuh, K. N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl224 · Cited by 806
Ambrose, P. G., Bhavnani, S. M., Rubino, C. M., Louie, A., Gumbo, T., Forrest, A., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510079 · Cited by 697
Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects
Muralidharan, G., Micalizzi, M., Speth, J., Raible, D., & Troy, S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.220-229.2005 · Cited by 333
Yaghoubi, S., Zekiy, A. O., Krutova, M., Gholami, M., Kouhsari, E., Sholeh, M., Ghafouri, Z., & Maleki, F. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04121-1 · Cited by 332
The Glycylcyclines: A Comparative Review with the Tetracyclines
Zhanel, G. G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., Karlowsky, J. A., & Hoban, D. J. (2004) · Drugs · doi:10.2165/00003495-200464010-00005 · Cited by 306
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose
Rodvold, K. A., Gotfried, M. H., Cwik, M., Korth-Bradley, J. M., Dukart, G., & Ellis-Grosse, E. J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl403 · Cited by 304
Pankey, G. A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki248 · Cited by 301
Tigecycline: A Critical Analysis
Stein, G. E., & Craig, W. A. (2006) · Clinical Infectious Diseases · doi:10.1086/505494 · Cited by 298
Self-citationMicroglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration
Purisai, M. G., McCormack, A. L., Cumine, S., Li, J., Isla, M. Z., & Di Monte, D. A. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.008 · Cited by 254
Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia
Rubino, C. M., Bhavnani, S. M., Forrest, A., Dukart, G., Dartois, N., Cooper, A., Korth-Bradley, J., & Ambrose, P. G. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00277-10 · Cited by 54
Metadata
- Authors
- van Ogtrop, M. L., Andes, D., Stamstad, T. J., Conklin, B., Weiss, W. J., Craig, W. A., & Vesga, O.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-04
- Volume
- 44
- Issue
- 4
- Pages
- 943-949
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2167119990
- Cited by
- 179
- References
- 0
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.